An angel syndicate is focused on life science tools and biotech infrastructure. The firm has a concentrated investment strategy targeting U.S.-based companies from the Pre-Seed to Series A stages. The firm’s investor base includes a select group of limited partners, about half of whom are active operators within the life science tools sector. The firm can co-invest but prefers to lead investments, with typical check sizes ranging from $160K to $2M. The firm brings deep domain expertise in life sciences and works closely with founders to build companies, pairing them with strategic capital. The firm is thesis-driven and leverages its extensive operator network, commercial reach, and M&A experience to accelerate company growth and strategy. The firm supports all aspects of business development, from financial modeling and strategic planning to connecting founders with key industry stakeholders within the life sciences ecosystem.
The firm exclusively targets life science tools, software, biotech infrastructure, and platform technologies that typically include a consumable component. The firm does not invest in therapeutics, diagnostics, digital health, or any business requiring FDA clearance. The firm is open to all development stages and all classes of tools, software, and platform technologies.
The firm only works with companies whose founders and teams are fully dedicated to their ventures. The firm generally prefers to take a board seat if it leads the investment round and if doing so aligns with the company’s stage of development.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment